Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18251079 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Non-Final OA | AbbVie Inc. |
| 18551428 | Compositions and Methods for Inhibiting and Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 18756960 | ITRACONAZOLE ANALOGS AND USE THEREOF | Non-Final OA | The Johns Hopkins University |
| 17291055 | COMPOSITIONS AND METHODS USING A COMBINATION OF CURCUMIN AND AN OMEGA-3 FATTY ACID FOR CELLULAR ENERGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17791110 | A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18065348 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | Non-Final OA | Massachusetts Institute of Technology |
| 17770686 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | SK BIOPHARMACEUTICALS CO., LTD. |
| 16966263 | ANALGESIC AGENT AND SEDATIVE AGENT | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 18043163 | HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS |
| 18289467 | MODULATORS OF TREX1 | Final Rejection | Constellation Pharmaceuticals, Inc. |
| 18262037 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | Non-Final OA | Baylor College of Medicine |
| 18721934 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18329491 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
| 18035543 | TREATMENT OF GAIT DYSFUNCTION IN NEURODEGENERATIVE DISEASE | Final Rejection | EIP Pharma, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy